TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06489951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin
Description: The outpatient physician prescribed Solinaxine (up to 0.5mg daily) to the participant orally

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin D
Description: The outpatient physician prescribed vitamin d drops (2400iu daily) for the participants, which were taken orally by the participants

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard behavioral therapy
Description: Participants will receive an initial behavioral therapy session at enrollment and a second behavioral therapy session six weeks later. Education including information about dry OAB, lifestyle adjustments, bladder and pelvic floor training, bowel management, and how to use a bladder diary to record urination

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard behavioral therapy
Description: Participants will receive an initial behavioral therapy session at enrollment and a second behavioral therapy session six weeks later. Education including information about dry OAB, lifestyle adjustments, bladder and pelvic floor training, bowel management, and how to use a bladder diary to record urination
Study: NCT06264843

Intervention type: DEVICE
Intervention: MiraQ with Transit-Time Flow Measurement (TTFM) and L15 High Frequency Ultrasound (HFUS) probes
Description: Identify and validate intraoperative TTFM and HFUS findings (e.g. threshold values of Mean Graft Flow (MGF), MGF capacity, flow curve pattern, morphological issues)
Study: NCT05388877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEK-1/MEKK-1 Inhibitor E6201
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study: NCT05972317

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low FODMAP dietary regimen
Description: intervention will include a guidance by a clinical dietitian about low FODMAP diet~The FODMAP diet has three phases:~1. Elimination - Avoidance from high-FODMAP foods (2-6 weeks)~2. Reintroduction -Structured challenges of specific food groups each time (6-8 weeks).~3. Maintenance - personalized diet, according to the response in step 2.
Study: NCT05967585

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Behavioral: Quitting Program (TIQ)
Description: Implementation processes developed in Phase 1 to develop assessment of vaping behaviors and referral to an evidence-based program for vaping cessation (TIQ) will be tested in Phase 2.~TIQ program is a mHealth, text messaging based intervention. Users who enroll in this program will receive 1 to 2 messages per day with 3 messages sent on their quit date. Messages are tailored to users' age, enrollment date or quit date, and the vape product they use.~Those not ready to quit receive 4 weeks of messages focused on building skills and confidence. Users who set a quit date receive messages for up to 6 weeks preceding the date and up to 8 weeks after that include encouragement, support, skill- and efficacy- building exercises, coping strategies, etc. Keywords such as COPE, STRESS, SLIP, and MORE can be used to request on-demand support.
Study: NCT06579261

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core Shamanism
Description: Each Shamanic intervention session, led by the shamanic practitioner, will include classical music as a control, followed by repetitive drumming and/or rattling music which the participant and shamanic practitioner will listen to for 15-30 mins. Following listening to drumming, the patient will then talk with the shamanic practitioner to debrief the experience of each session. Participants will also listen to classical music as a control stimulus.
Study: NCT05732311

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intermittend theta burst stimulation
Description: intermittend theta burst stimulation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: intermittend theta burst stimulation
Description: intermittend theta burst stimulation
Study: NCT06566989

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [¹⁴C]Opevesostat
Description: Oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludrocortisone
Description: Tablet
Study: NCT05349487

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SpeakFree HME Hands Free Valve
Description: A voice prosthesis, SpeakFree HME Hands Free Valve, achieved with creation of a tracheoesophageal puncture will be placed over the stoma for 1 month.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Digital Occlusion
Description: Using participant's own fingers, they will be putting their fingers over the stoma.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digital Depression HME
Description: A digital handheld press-down HME will be placed over stoma.
Study: NCT06582160

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Risk-Based Pre-conception Screening
Description: A long form questionnaire screening questionnaire administered via tablet in health clinic waiting room. Offered to patients when patient checks-in for appointment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient-centered Pre-conception Screening
Description: A short form, 2 question screening administered via tablet in health clinic waiting room. Offered to patients when patient checks-in for appointment.
Study: NCT05122806

Intervention type: GENETIC
Group type: OTHER
Intervention: RNAseq
Description: 1. Tissue : RNAseq will be performed on tumor biopsy (10 slides of 5 microns) to identify the ALK fusion partner and its variant and associated co-mutations.~2. ctDNA : NGS panel on DNA including a large panel of fusions and mutations will be performed on blood samples
Study: NCT05132556

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Acute Beetroot Juice
Description: Participants will ingest a beetroot juice supplement with and without inorganic nitrate to determine the effects of acute dietary nitrate ingestion on blood pressure and arterial stiffness

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute Beetroot Juice
Description: Participants will ingest a beetroot juice supplement with and without inorganic nitrate to determine the effects of acute dietary nitrate ingestion on blood pressure and arterial stiffness
Study: NCT05274997

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YY-20394
Description: Linperlisib is a strong and selective small-molecule PI3K-δ (a protein involves in the survival of cells) inhibitor, which is able to interfere with the growth, migration and survival of T/NK lymphoma cells.
Study: NCT05543187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-625
Description: TAK-625 orally, twice daily (BID)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-625
Description: TAK-625 orally, twice daily (BID)
Study: NCT06322979

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mineral trioxide aggregate
Description: Apexification treatment was done with mineral trioxide aggregate

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Premixed Bioceramic Putty
Description: Apexification treatment was done with Premixed Bioceramic Putty (Well-Root™ PT)
Study: NCT05778877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEL-302
Description: SEL-302 Drug: MMA-101 (1.0E13 vg/kg)~Drug: SEL-110 (0.15 mg/kg or up to 0.3 mg/kg)~Other Names:~SEL-110.36, ImmTOR

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEL-302
Description: SEL-302 Drug: MMA-101 (1.0E13 vg/kg)~Drug: SEL-110 (0.15 mg/kg or up to 0.3 mg/kg)~Other Names:~SEL-110.36, ImmTOR
Study: NCT06235944

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Caudal block
Description: Patients were received (plain bupivacaine 0.25% 1 mg/kg + 2 % lidocaine 3 mg /kg) in total volume 1ml/ kg max 20 ml via Ultrasound Guided caudal Block.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sacral erector spinae block
Description: Patients were received (plain bupivacaine 0.25% 1 mg/kg + 2 % lidocaine 3 mg /kg) in total volume of 1 ml/ kg maximum 20ml divided in both sides via ultrasound guided sacral erector spinae plain block (ESPB).
Study: NCT05391737

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography
Description: Echocardiography after swimming (acute) and at rest (baseline)

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography
Description: Echocardiography after swimming (acute) and at rest (baseline)

Intervention type: DIAGNOSTIC_TEST
Intervention: Electrocardiogram (ECG)
Description: Electrocardiogram (ECG) after swimming (acute) and at rest (baseline)

Intervention type: DIAGNOSTIC_TEST
Intervention: Electrocardiogram (ECG)
Description: Electrocardiogram (ECG) after swimming (acute) and at rest (baseline)

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac biomarkers
Description: high sensitive (hs)-Troponin I and N-terminal pro-brain natriuretic peptide (NT-pro-BNP) after swimming (acute) and at rest (baseline)

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac biomarkers
Description: high sensitive (hs)-Troponin I and N-terminal pro-brain natriuretic peptide (NT-pro-BNP) after swimming (acute) and at rest (baseline)
Study: NCT05467059

Intervention type: OTHER
Intervention: Napping
Description: Patients are already equipped with electrodes when they pass a test battery before the nap to evaluate mechanisms potentially correlated with tinnitus modulation. Then they do a nap, the nap is stopped when several periods of sleep are seen on EEG (electroencephalogram). Then the test battery is done backwards to evaluate the same measures.
Study: NCT05706298

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active Breaks
Description: Participants will be asked to interrupt sitting with 3 min bouts of walking every 30 min from 9am-5pm
Study: NCT05338684

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Colour doppler,MSCT,MRI
Description: ultrasound/color duplex at Jugular veins \& carotid and vertebral arteries first ,then MSCT/CTA mainly with relation of neck \& Bain arteries to the bone of the skull in 6 mm cuts and/or MRI/MRA/MRV by standardized multi-parametric MR protocol will be implemented for all patients. All sequences will be acquired on a 1.5T MR scanner.
Study: NCT05939453

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Light
Description: Sham treatment will be provided from a light box at a distance of at least 70cm but no greater than 90cm.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bright Light Therapy
Description: Bright Light Therapy will be provided using light box with an artificial full spectrum lamp at a distance of at least 70cm but no greater than 90cm.
Study: NCT04271878

Intervention type: OTHER
Group type: OTHER
Intervention: RespirAct™ system (Thornhill Research Inc., Toronto, Canada)
Description: 1. HUTT with Normal Breathing in Room Air (No gas interventions will be applied)~2. HUTT with Normal Breathing and ETCO2 clamped at baseline levels~3. HUTT with Normal Breathing and Mild Hypercapnia (the ETCO2 will be clamped at 45mmHg )~4. HUTT with Normal Breathing and High Hypercapnia (the ETCO2 will be clamped at 55mmHg)~5. HUTT with Fast, Deep Breathing and resultant Hypocapnia Participant will be coached to breath around 15 breath per min.No gas interventions will be applied~6. HUTT with Fast, Deep Breathing and ETCO2 clamped at baseline levels. Participant will be coached to breath around 15 breath per min, with ETCO2 clamped to baseline levels.
Study: NCT06016309

Intervention type: OTHER
Intervention: There is no intervention.
Description: There is no intervention.

Intervention type: OTHER
Intervention: There is no intervention.
Description: There is no intervention.
Study: NCT05910684

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Aegis CDM Test and Educational Materials
Description: The Aegis CDM diagnostic test will be given to intervention participants to use on their patients. The participants will receive the results of the test through a web portal. Investigators will analyze the differences in quality of care between the control arm and the intervention arm.
Study: NCT05409625

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intraoral Scanner (TRIOS 4, 3Shape TRIOS A/S, Copenhagen, Denmark)
Description: Intraoral scanner which is able to generate a 3D-model of the teeth and is being used for caries detection.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intraoral camera (DIAGNOcam, KaVo, Biberach, Germany, software version 3.0.1/2.9.1)
Description: Intraoral camera used for caries detection in the occlusal and proximal surfaces.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: X-ray device (X-ray device SOREDEX, MINRAY®; Image plates VistaScan; Image plate scanner VistaScan Mini View, Dürr Dental)
Description: X-ray device used for caries detection. Two radiographs (bitewings) are taken, one in each side.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oral cleaning
Description: Removal of tartar and plaque. Tartar removal done at baseline and the fifth visit, but only on selected teeth at the second, third and fourth visit. Regular cleaning with a toothbrush done at all visits.
Study: NCT06296069

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exergame-based cognitive-motor training on an unstable surface
Description: The intervention group will receive an exergame-based cognitive-sensorimotor intervention on an unstable surface (by placing the exergame device (Senso) on an unstable surface).~The Senso is a platform for the dynamic recording of steps, weight shifts and other body movements producing forces. For the labile condition, the Senso is mounted on steel balls, allowing the platform to swing freely along the horizontal plane. There is no movement induced by the platform itself. Sway is only induced when the participant steps and shifts the center of pressure. The degree of instability and movement of the platform can be adjusted by inducing a dampening. The dampening can be set manually, either to on or off. When damping is on, the movement can be reduced by predefined percentages. The maximum displacement of the platform is thereby 100 mm to each side.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exergame-based cognitive-motor training on an stable surface
Description: The control group will receive an exergame-based cognitive-motor intervention on an stable surface using the exergame device Senso.~The Senso is a platform for the dynamic recording of steps, weight shifts and other body movements producing forces.
Study: NCT05665634

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Concurrent transcranial magnetic stimulation and electroencephalogram
Description: Single and paired-pulse TMS will be applied to 5 different brain regions during simultaneous recording of EEG. Paired-pulse stimulations will have either 3 ms or 11 ms between pulses, to stimulate cortical inhibition and excitation respectively. Stimulation intensity for single-pulse stimulation blocks will be 120% of the resting motor threshold (RMT). For paired-pulse blocks, the conditioning (first) pulse will be delivered at a stimulation intensity of 80% RMT, and the test (second) pulse will be delivered at 120% RMT. Each test block will consist of 60 TMS trials and will last for 5 minutes. Order of test blocks will be pseudo-randomized across participants. Out of 5 stimulation sites, 3 will be determined based on individual's own brain anatomy and resting state connectivity. These 3 regions will be stimulated using all 3 TMS protocols. The other two regions will be determined based on the literature and only be targeted using the single pulse TMS protocol.
Study: NCT06346717

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Knee Prosthesis-M mobile application service
Description: In the early phase of mobile application development, qualitative interviews will be conducted with patients with total knee arthroplasty (TKA) experience regarding their own surgery experiences. A training booklet for Knee prosthesis-M will be created, taking into account the literature and patient feedback. Then, the Knee prosthesis-M application design will be completed. One day before surgery; Written consent will be obtained from patients who meet the criteria via an Informed Consent Form. Patients in the intervention group will access the Knee Prosthesis-M application from their smartphones and will be asked to use it actively for 6 weeks, starting from the 1st day of the surgery. Mobile application-supported care will be provided to the patients by sending information, warning and reminder messages to the patients for 6 weeks.
Study: NCT06038539

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PERT-IJS plus trastuzumab, carboplatin and docetaxel
Description: PERT-IJS is a monoclonal antibody, which has been developed by Biocon Biologics (earlier in collaboration with Viatris) as a proposed biosimilar to European Union (EU)-approved and United States (US) licensed Perjeta.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Perjeta plus trastuzumab, carboplatin and docetaxel
Description: EU Perjeta (Pertuzumab) , an antineoplastic agent, is a recombinant humanized monoclonal antibody that specifically targets sub-domain 2 of the extracellular domain of Human Epidermal Growth Factor Receptor 2 (HER2), blocking heterodimerization of HER2 with other members of the receptor family, including epidermal growth factor, Human Epidermal Growth Factor Receptor 3 (HER3) and Human Epidermal Growth Factor Receptor 4 (HER4).
Study: NCT05447052

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bio-MIMICS 3D Stent
Description: Bio-MIMICS Stent implantation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Innova Stent
Description: Innova Stent implantation
Study: NCT03770546

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Amnion Injection
Description: Per the manufacturer, this is considered an injection of tissue/organic matter.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Amnion Injection
Description: Per the manufacturer, this is considered an injection of tissue/organic matter.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betamethasone injection
Description: Routine steroid injection for these pathologies. Betamethasone Sodium Phosphate and Betamethasone Acetate injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betamethasone injection
Description: Routine steroid injection for these pathologies. Betamethasone Sodium Phosphate and Betamethasone Acetate injection.
Study: NCT05176288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: Taken Orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Taken Orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Intravenous infusion
Study: NCT05733546

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Psilocybin
Description: COMP360 Psilocybin administered under supportive conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: COMP360 Psilocybin administered under supportive conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: COMP360 Psilocybin administered under supportive conditions
Study: NCT04596267

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pitolisant
Description: 8.9mg Pitolisant for 5 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inert ingredients
Study: NCT05846347

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GC012F injection
Description: Each subject will receive GC012F injection (CD19-BCMA CAR-T cells) once by intravenous infusion on Day 0.
Study: NCT06124287

Intervention type: DIAGNOSTIC_TEST
Intervention: MR Enterography (MRE)
Description: MRI scan
Study: NCT05060068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-ketamine (low dose)
Description: Patients in the low-dose ketamine group will receive a bolus of 0.5 mg/kg S-ketamine in saline, followed by continuous infusion of 2 μg/kg/min S-ketamine in saline until 30 min prior to the end of the surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients in the placebo group will receive a bolus of 0.9% saline, followed by continuous infusion of 0.9% saline until 30 min prior to the end of the surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-ketamine (high dose)
Description: Patients in the high-dose ketamine group will receive a bolus of 0.5 mg/kg S-ketamine in saline, followed by continuous infusion of 4 μg/kg/min S-ketamine in saline until 30 min prior to the end of the surgery.
Study: NCT05813977

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tritube
Description: The patient is intubated with Tritube® after the removal of the conventional endotracheal tube (ETT) and Tritube® was advanced until proximal to the carina. Before starting the PDT, measurements with ATP bioluminescence-based method (3M Clean-trace®) were made by taking sample from a sterile PVC surface (10 cm2) which is held 50 cm over the operation site. After PDT with Griggs method (Portex), the measurements were repeated by taking sample from surface.
Study: NCT05235230

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test product (T) 25 mg Film Coated Tablets
Description: Film Coated Tablets products containing 25 mg Quetiapine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reference product (R) 25 mg Film Coated Tablets
Description: Reference product (R) 25 mg Film Coated Tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reference product (R) 25 mg Film Coated Tablets
Description: Reference product (R) 25 mg Film Coated Tablets
Study: NCT06035159

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: online psychotherapy
Description: 6 modules
Study: NCT05168202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-95251
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-95251
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Specified dose on specified days
Study: NCT06446089

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: THP: cognitive behavior therapy and behavioral activation
Description: The adapted THP takes into account cultural and linguistic characteristics of the participants. Participants will be invited to complete three modules on an Android based app on their mobile, populated with information and activities from the adapted THP.
Study: NCT06070454

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Vaginitis panel
Description: vulvovaginal swab to test for the most common causes of vulvovaginitis - bacterial vaginosis (BV), trichomonas, and candida